[go: up one dir, main page]

WO2023248010A3 - Modulateurs ciblés de jak3 pour le traitement de maladies inflammatoires et auto-immunes - Google Patents

Modulateurs ciblés de jak3 pour le traitement de maladies inflammatoires et auto-immunes Download PDF

Info

Publication number
WO2023248010A3
WO2023248010A3 PCT/IB2023/000382 IB2023000382W WO2023248010A3 WO 2023248010 A3 WO2023248010 A3 WO 2023248010A3 IB 2023000382 W IB2023000382 W IB 2023000382W WO 2023248010 A3 WO2023248010 A3 WO 2023248010A3
Authority
WO
WIPO (PCT)
Prior art keywords
jak3
inflammatory
treatment
autoimmune diseases
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2023/000382
Other languages
English (en)
Other versions
WO2023248010A2 (fr
Inventor
Julian LAUX
Jan-Hinrich Guse
Stefan Laufer
Michael W. BURNET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synovo GmbH
Original Assignee
Synovo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synovo GmbH filed Critical Synovo GmbH
Publication of WO2023248010A2 publication Critical patent/WO2023248010A2/fr
Publication of WO2023248010A3 publication Critical patent/WO2023248010A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs de JAK3 qui contiennent une combinaison de 2 ou plus des fractions suivantes : un accepteur de Michael contenant un cyano, une 1,6-dihydroimidazo[4,5-d]pyrrolo [2,3-b]pyridine, et un facteur de ciblage pour augmenter l'absorption et l'exposition de cellules myéloïdes.
PCT/IB2023/000382 2022-06-23 2023-06-23 Modulateurs ciblés de jak3 pour le traitement de maladies inflammatoires et auto-immunes Ceased WO2023248010A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263355065P 2022-06-23 2022-06-23
US63/355,065 2022-06-23

Publications (2)

Publication Number Publication Date
WO2023248010A2 WO2023248010A2 (fr) 2023-12-28
WO2023248010A3 true WO2023248010A3 (fr) 2024-03-07

Family

ID=87930127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/000382 Ceased WO2023248010A2 (fr) 2022-06-23 2023-06-23 Modulateurs ciblés de jak3 pour le traitement de maladies inflammatoires et auto-immunes

Country Status (1)

Country Link
WO (1) WO2023248010A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055531A1 (fr) * 2001-01-09 2002-07-18 Pliva D.D. Conjugues de composes de macrolide specifiques de cellules immunitaires avec des composes anti-inflammatoires, permettant un ciblage cellulaire ameliore d'une therapie anti-inflammatoire
WO2004005309A2 (fr) * 2002-07-08 2004-01-15 Pliva - Istrazivacki Institut D.O.O. Substances anti-inflammatoires non steroidiennes, compositions et procedes d'utilisation de celles-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219770B2 (en) 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7767797B1 (en) 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
CA2703600C (fr) 2007-11-15 2017-04-25 Ym Biosciences Australia Pty Ltd Composes heterocycliques de thieno ou pyrrolo pyrimidine fusionnes et leur utilisation comme inhibiteurs de jak1, jak2 ou jak3
AU2010239396B2 (en) 2009-04-20 2016-06-23 Auspex Pharmaceuticals, Llc Piperidine inhibitors of Janus Kinase 3
EP2493895B1 (fr) 2009-10-29 2017-04-26 Vectura Limited Dérivés d'hétéroaryle contenant de l'azote en tant qu'inhibiteurs jak3
CA2789847A1 (fr) 2010-02-15 2011-08-18 Synovo Gmbh Modulateurs de kinase pour le traitement du cancer
US9221826B2 (en) 2011-03-17 2015-12-29 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
SG11201503977PA (en) 2012-11-20 2015-06-29 Principia Biopharma Inc Azaindole derivatives as jak3 inhibitors
CA3039202A1 (fr) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055531A1 (fr) * 2001-01-09 2002-07-18 Pliva D.D. Conjugues de composes de macrolide specifiques de cellules immunitaires avec des composes anti-inflammatoires, permettant un ciblage cellulaire ameliore d'une therapie anti-inflammatoire
WO2004005309A2 (fr) * 2002-07-08 2004-01-15 Pliva - Istrazivacki Institut D.O.O. Substances anti-inflammatoires non steroidiennes, compositions et procedes d'utilisation de celles-ci

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FORSTER MICHAEL ET AL: "Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d ]pyrrolo[2,3- b ]pyridine Scaffold", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 12, 31 May 2018 (2018-05-31), US, pages 5350 - 5366, XP055947983, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00571 *
FORSTER MICHAEL ET AL: "Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket", CELL CHEMICAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 11, 10 November 2016 (2016-11-10), pages 1335 - 1340, XP029812475, ISSN: 2451-9456, DOI: 10.1016/J.CHEMBIOL.2016.10.008 *
LAUX JULIAN ET AL: "Inherent Fluorescence Demonstrates Immunotropic Properties for Novel Janus Kinase 3 Inhibitors", ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, vol. 6, no. 10, 21 September 2023 (2023-09-21), pages 1433 - 1452, XP093102459, ISSN: 2575-9108, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsptsci.3c00119> DOI: 10.1021/acsptsci.3c00119 *
LAUX JULIAN ET AL: "Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells", ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, vol. 5, no. 8, 14 July 2022 (2022-07-14), pages 573 - 602, XP093102453, ISSN: 2575-9108, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsptsci.2c00054> DOI: 10.1021/acsptsci.2c00054 *

Also Published As

Publication number Publication date
WO2023248010A2 (fr) 2023-12-28

Similar Documents

Publication Publication Date Title
MY152386A (en) Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
CO5660266A2 (es) Sal de acido fosforico de un inhibidor de la dipeptidil peptidasa-iv
MX2009004700A (es) Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
PH12013501001A1 (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
PE20140390A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
GEP20094720B (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
AU6422399A (en) 6-substituted pyrazolo(3,4-d)pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
NO20081523L (no) Fremstilling og anvendelse av tetrahydropyrrolo(3,2-C)Pyridin-4-on-derivater for behandling av fedme, psykiatriske og neurologiske forstyrrelser
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
NZ623922A (en) Novel tricyclic compounds
WO2007044050A3 (fr) Composés tricycliques basés sur la 1h-imidazo[4,5-d]thiéno[3,2-b]pyridine et préparations pharmaceutiques les incluant
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
MX2025002794A (es) Compuestos citotoxicos de imidazo[1,2-a]piridina y su uso en terapia
WO2022058745A3 (fr) Nouveaux composés et leur utilisation en thérapie
WO2023248010A3 (fr) Modulateurs ciblés de jak3 pour le traitement de maladies inflammatoires et auto-immunes
PT4259632T (pt) Derivados de n-(imidazo[1,2-b]piridazin-3-il)-1- ciclohexil-2h-indazol-5-carboxamida e n-(pirazolo[1,5- a]pirimidina-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inibidores de irak4 para o tratamento da asma
CA2342830A1 (fr) Pyrazolo[4,3-d]-pyrimidin-7-ones 5-heterocyclyle, servant au traitement des troubles de l&#39;erection chez l&#39;homme
CA3266687A1 (fr) Dérivés pyrazolo[1,5-a]pyridine et imidazo[1,2-a]pyridine en tant qu’inhibiteurs de fgfr3 pour le traitement du cancer
ZA202102974B (en) 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
CA3250387A1 (fr) Composés de tétrahydropyrido[3,4-d]pyrimidines utilisés en tant qu&#39;inhibiteurs de hpk1
BR112023018593A2 (pt) Processo
HK40103397A (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23764988

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23764988

Country of ref document: EP

Kind code of ref document: A2